20多年来，罗氏致力于为血液病患者开发药物，在这一治疗领域积累了丰富的经验与知识。现如今，罗氏的投入远超以往，努力为各类血液病患者提供创新的治疗选择。目前公司获批的药物包括美罗华^{®<\/sup>（利妥昔单抗）、佳罗华^{®<\/sup>（奥妥珠单抗）、优罗华^{®<\/sup>（维泊妥珠单抗）、高罗华^{®<\/sup>（格菲妥单抗），皓罗华^{®<\/sup>（莫妥珠单抗）和舒友立乐^{®<\/sup>（艾美赛珠单抗）。罗氏的科学专业知识，加上广泛的产品组合和产品线，也为开发进一步改善患者生活的联合治疗方案提供了独特的机会。<\/p> \n}}}}}}

罗氏是一家全球领先的生物技术企业，总部在瑞士，拥有125余年悠久历史。结合制药和诊断两大领域的独特优势，我们致力于通过个体化医疗推动科学进步，改善人类生活。作为全球制药和诊断领域的领导者，罗氏在抗肿瘤、免疫、抗感染、眼科和神经科学系统领域拥有一流的差异化药物。创新是罗氏的DNA。作为一家以创新为驱动的制药公司，每年，罗氏集团在研发创新领域投入巨大。2021年，罗氏全球的研发投入达到150亿美元，约占公司收入的20%。<\/p> \n

\n \n \n \n \n \n \n \n

^{[1]<\/sup> <\/span> FDA approves Roche's Columvi, the first and only bispecific：https:\/\/www.globenewswire.com\/news-release\/2023\/06\/16\/2689505\/0\/en\/FDA-approves-Roche-s-Columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treatment-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html<\/a> <\/span> <\/p> <\/td> \n <\/tr> \n}

^{[2]<\/sup> <\/span> Coiffier B, et al. Blood. 2010;116(12):2040-2045.<\/span> <\/p> <\/td> \n <\/tr> \n}

^{[3]<\/sup> <\/span> Hoffmann MS, et al. Transplant Cell Ther. 2023;29(7):440-448.<\/span> <\/p> <\/td> \n <\/tr> \n}

^{[4] <\/sup> <\/span>Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940-1954. doi:10.1016\/S0140-6736(24)01774-4<\/span> <\/p> <\/td> \n <\/tr> \n}

^{[5]<\/sup> <\/span> Roche's Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma：https:\/\/www.roche.com\/media\/releases\/med-cor-2024-06-15#:~:text=Basel%2C%2015%20June%202024%20-%20Roche%20%28SIX%3A%20RO%2C,2024%20Congress%20as%20a%20late-breaking%20oral%20presentation.%201<\/a> <\/span> <\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
<\/p> \n $\"\"$ "]; $("#dvExtra").html(content_array[0]);})();